Myelofibrosis

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

(Redirected from Myeloid metaplasia)
Jump to: navigation, search
Myelofibrosis
Classification and external resources
Bone marrow: Myelofibrosis: High mag H&E excellent example of myelofibrosis.
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology
ICD-10 C94.5, D47.1
ICD-9 289.89
ICD-O: 9932, 9961
DiseasesDB 8616
MeSH D009191

WikiDoc Resources for

Myelofibrosis

Articles

Most recent articles on Myelofibrosis

Most cited articles on Myelofibrosis

Review articles on Myelofibrosis

Articles on Myelofibrosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Myelofibrosis

Images of Myelofibrosis

Photos of Myelofibrosis

Podcasts & MP3s on Myelofibrosis

Videos on Myelofibrosis

Evidence Based Medicine

Cochrane Collaboration on Myelofibrosis

Bandolier on Myelofibrosis

TRIP on Myelofibrosis

Clinical Trials

Ongoing Trials on Myelofibrosis at Clinical Trials.gov

Trial results on Myelofibrosis

Clinical Trials on Myelofibrosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Myelofibrosis

NICE Guidance on Myelofibrosis

NHS PRODIGY Guidance

FDA on Myelofibrosis

CDC on Myelofibrosis

Books

Books on Myelofibrosis

News

Myelofibrosis in the news

Be alerted to news on Myelofibrosis

News trends on Myelofibrosis

Commentary

Blogs on Myelofibrosis

Definitions

Definitions of Myelofibrosis

Patient Resources / Community

Patient resources on Myelofibrosis

Discussion groups on Myelofibrosis

Patient Handouts on Myelofibrosis

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis

Healthcare Provider Resources

Symptoms of Myelofibrosis

Causes & Risk Factors for Myelofibrosis

Diagnostic studies for Myelofibrosis

Treatment of Myelofibrosis

Continuing Medical Education (CME)

CME Programs on Myelofibrosis

International

Myelofibrosis en Espanol

Myelofibrosis en Francais

Businness

Myelofibrosis in the Marketplace

Patents on Myelofibrosis

Experimental / Informatics

List of terms related to Myelofibrosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Myelofibrosis with myeloid metaplasia, also known as agnogenic myeloid metaplasia, chronic idiopathic myelofibrosis, and primary myelofibrosis,[1] was first described in 1879 and is currently classified as a myeloproliferative disease caused by the growth and proliferation of an abnormal bone marrow stem cell, resulting in the replacement of the bone marrow with fibrous connective tissue. An eponym for the disease is Heuck-Assmann disease, or Assmann's Disease.

Presentation

The bone marrow is replaced by collagen fibrosis, impairing the patient's ability to generate new blood cells resulting in a progressive anemia. It is usually reactive following other myeloproliferative disorders, such as polycythemia rubra vera or essential thrombocytosis. Extramedullary hematopoeisis occurs as the haemopoetic cells migrate away from the bone marrow, to the liver and spleen. Patients often have hepatosplenomegaly and poikilocytosis. The mean survival is 5 years and causes of death include infection, bleeding, organ failure, portal hypertension, and leukemic transformation.

Diagnosis

Diagnosis is based upon:

  1. Normochromic normocytic anaemia
  2. Red cell poikilocytosis on blood film (tear drop RBCs)
  3. JAK 2 mutation on Val 617 Phe locus in 50%
  4. Raised lactate dehydrogenase
  5. Raised neutrophil alkaline phosphatase score
  6. Bone marrow biopsy may show increased cellularity and fibrosis

References


bn:মজ্জাকাঠিন্য

de:Osteomyelofibrose fr:Splénomégalie myéloïde it:Mielofibrosi


WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools
In other languages